Amgen Inc. $AMGN Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 64.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,119 shares of the medical research company’s stock after selling 40,898 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Amgen were worth $7,240,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Board of the Pension Protection Fund acquired a new position in shares of Amgen during the 4th quarter valued at $26,000. Howard Hughes Medical Institute acquired a new stake in Amgen in the 2nd quarter valued at $32,000. Olistico Wealth LLC acquired a new stake in Amgen in the 4th quarter valued at $33,000. Cloud Capital Management LLC purchased a new position in Amgen in the third quarter valued at about $34,000. Finally, Saranac Partners Ltd purchased a new position in Amgen in the third quarter valued at about $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $348.77 on Monday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The firm has a market cap of $188.01 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 3.46 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock’s 50-day simple moving average is $362.59 and its 200-day simple moving average is $330.59.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the firm posted $5.31 earnings per share. The company’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Truist Financial raised their target price on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Wells Fargo & Company boosted their price target on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Finally, Cantor Fitzgerald lifted their price objective on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.